Acute Myeloid Leukemia (AML)
13 competing products in clinical development for Acute Myeloid Leukemia (AML).
Pipeline by Phase
Pre-clinical2
Phase 14
Phase 1/25
Phase 21
Phase 31
All Products (13)
| Product | Company | Stage | Status | Hype |
|---|---|---|---|---|
| gilteritinib + azacitidine | Astellas Pharma | Phase 3 | Completed | 40 |
| Gilteritinib + Venetoclax + Azacitidine | Astellas Pharma | Phase 1/2 | Active | 36 |
| Gilteritinib + Ivosidenib + Enasidenib | Astellas Pharma | Phase 1 | Recruiting | 36 |
| Gilteritinib + Placebo | Astellas Pharma | Phase 2 | Completed | 35 |
| gilteritinib + atezolizumab | Astellas Pharma | Phase 1/2 | Completed | 32 |
| ASP7517 | Astellas Pharma | Phase 1/2 | Completed | 32 |
| Quizartinib | Daiichi Sankyo | Phase 1 | Completed | 29 |
| Venetoclax + Gilteritinib | Astellas Pharma | Phase 1 | Completed | 29 |
| Gilteritinib | Astellas Pharma | Phase 1 | Completed | 29 |
| gilteritinib | Astellas Pharma | Pre-clinical | Completed | 26 |
| gilteritinib | Astellas Pharma | Pre-clinical | Completed | 26 |
| gilteritinib + fludarabine + cytarabine + granulocyte colony-stimulating factor (G-CSF) | Astellas Pharma | Phase 1/2 | Terminated | 24 |
| ZN-d5 ZN-c3 + ZN-c3 | Zentalis Pharmaceuticals | Phase 1/2 | Terminated | 14 |